Crizanlizumab rollover study for people with sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to sign a consent form (or have a parent/guardian sign for youth) before starting.
- You must have completed a prior Novartis crizanlizumab study and be currently receiving crizanlizumab from that study.
- Your doctor should think the treatment is helping you and that you finished the earlier treatment plan as planned.
- You must have followed the visit schedule in the prior study and be willing/able to keep coming for future study visits.
- You must not have stopped crizanlizumab permanently before the earlier study ended, and you should not have serious side effects that haven’t resolved yet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This study helps connect adults with sickle cell disease who haven't seen a specialist in over a year back into care. It tests a program designed to make it easier to get regular medical support and improve your health.
This early trial tests crizanlizumab (a medicine for sickle cell) to see if it improves how your body matches oxygen supply with oxygen needs. It may be helpful for reducing sickle-cell–related complications by changing blood vessel and oxygen behavior.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.